These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7962469)

  • 1. Pharmacology of two new very selective antiprogestagens: Org 31710 and Org 31806.
    Kloosterboer HJ; Deckers GH; Schoonen WG
    Hum Reprod; 1994 Jun; 9 Suppl 1():47-52. PubMed ID: 7962469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of a new selective antiprogestagen: Org 33628.
    Kloosterboer HJ; Deckers GH; de Gooyer ME; Dijkema R; Orlemans EO; Schoonen WG
    Ann N Y Acad Sci; 1995 Jun; 761():192-201. PubMed ID: 7625721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium.
    Kloosterboer HJ; Deckers GH; Schoonen WG; Hanssen RG; Rose UM; Verbost PM; Hsiu JG; Williams RF; Hodgen GD
    Steroids; 2000; 65(10-11):733-40. PubMed ID: 11108884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptor antagonists and prostaglandins in human fertility regulation: a clinical review.
    Healy DL
    Reprod Fertil Dev; 1990; 2(5):477-90. PubMed ID: 1963697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiprogestins and iatrogenic glucocorticoid resistance.
    Koper JW; Molijn GJ; van Uffelen CJ; Stigter E; Lamberts SW
    Life Sci; 1997; 60(9):617-24. PubMed ID: 9048964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.
    Fuhrmann U; Hess-Stumpp H; Cleve A; Neef G; Schwede W; Hoffmann J; Fritzemeier KH; Chwalisz K
    J Med Chem; 2000 Dec; 43(26):5010-6. PubMed ID: 11150172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat.
    Schneider MR; Michna H; Nishino Y; el Etreby MF
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):691-701. PubMed ID: 2497018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The antiprogesterone action of mifepristone].
    Willems F
    Ned Tijdschr Geneeskd; 1989 Jun; 133(22):1139-40. PubMed ID: 2739799
    [No Abstract]   [Full Text] [Related]  

  • 9. Contragestion by the progesterone antagonist RU 486: a novel approach to human fertility control.
    Baulieu EE
    Contraception; 1987; 36 Suppl():1-5. PubMed ID: 2824124
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical uses of antiprogestogens.
    Van Look PF; von Hertzen H
    Hum Reprod Update; 1995 Jan; 1(1):19-34. PubMed ID: 9080204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
    Lee O; Choi MR; Christov K; Ivancic D; Khan SA
    Cancer Lett; 2016 Jul; 376(2):310-7. PubMed ID: 27080304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestin action and progesterone receptor structure in human breast cancer: a review.
    Horwitz KB; Wei LL; Sedlacek SM; d'Arville CN
    Recent Prog Horm Res; 1985; 41():249-316. PubMed ID: 3931189
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of a 17alpha-(3-hydroxypropyl)-17beta-acetyl substituent pattern on the glucocorticoid and progestin receptor binding of 11beta-arylestra-4,9-dien-3-ones.
    Cook CE; Raje P; Lee DY; Kepler JA
    Org Lett; 2001 Apr; 3(7):1013-6. PubMed ID: 11277783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
    Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
    Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Initial Dutch experiences with early pregnancy interruption using the antiprogesterone agent mifepriston].
    Vervest HA; Haspels AA
    Ned Tijdschr Geneeskd; 1985 Aug; 129(35):1680-3. PubMed ID: 4047227
    [No Abstract]   [Full Text] [Related]  

  • 16. Relative binding affinity of antiprogestins ZK 98.299 and ZK 98.734 for progesterone receptors in the endometrium and myometrium of bonnet monkeys.
    Pongubala JM; Elger WA; Puri CP
    J Recept Res; 1987; 7(6):903-20. PubMed ID: 3450874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical uses of the antiprogestin RU 486 (mifepristone). Proceedings of a Roussel-UCLAF satellite symposium. Singapore, 30th October 1986.
    Contraception; 1987; 36 Suppl():1-42. PubMed ID: 2824123
    [No Abstract]   [Full Text] [Related]  

  • 18. History and perspectives of antiprogestins from the chemist's point of view.
    Teutsch G; Philibert D
    Hum Reprod; 1994 Jun; 9 Suppl 1():12-31. PubMed ID: 7962457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models.
    Kloosterboer HJ; Schoonen WG; Deckers GH; Klijn JG
    J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):311-8. PubMed ID: 8043494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal progestins and antiprogestins related to flutamide.
    Dukes M; Furr BJ; Hughes LR; Tucker H; Woodburn JR
    Steroids; 2000; 65(10-11):725-31. PubMed ID: 11108883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.